In-Fusion is hoping to develop a new drug to attack and kill leukaemia cells. The firm will start operations next year (t=1). Exhibit 1 shows financial projections for years 0 through 6. Starting in year 7, EBIT as well as Assets are expected to grow at 3% per year in perpetuity. Please make the following assumptions:
1. The risk-free rate is 4% and the market risk premium is 5%.
2. The CAPM required rate of return on assets is 11.5% (i.e. βA = 1.5).
3. The corporate tax rate is 35%.
4. The firm has $200 million in debt yielding 7% (2 percentage points above its expected return). Debt is expected to remain at the $200 million level for the indefinite future.
What is the DCF value of In-Fusion?